Growth Metrics

Ligand Pharmaceuticals (LGND) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $86.2 million.

  • Ligand Pharmaceuticals' Non Operating Income rose 100915.42% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 14602.49%. This contributed to the annual value of -$54.9 million for FY2024, which is 20618.74% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Non Operating Income stood at $86.2 million for Q3 2025, which was up 100915.42% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Non Operating Income ranged from a high of $110.5 million in Q1 2024 and a low of -$109.6 million during Q4 2024
  • Over the past 5 years, Ligand Pharmaceuticals' median Non Operating Income value was $677000.0 (recorded in 2022), while the average stood at $3.7 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Non Operating Income tumbled by 234844.9% in 2023 and then skyrocketed by 100915.42% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Non Operating Income (Quarter) stood at -$19.8 million in 2021, then surged by 323.33% to $44.2 million in 2022, then tumbled by 53.76% to $20.5 million in 2023, then plummeted by 635.83% to -$109.6 million in 2024, then soared by 178.65% to $86.2 million in 2025.
  • Its Non Operating Income was $86.2 million in Q3 2025, compared to $2.8 million in Q2 2025 and -$14.0 million in Q1 2025.